KALV KalVista Pharmaceuticals Inc.

+0.02  (+0%)
Previous Close 17
Open 16.83
Price To Book 2.82
Market Cap 293,549,863
Shares 17,247,348
Volume 10,149
Short Ratio
Av. Daily Volume 193,061

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
Diabetic macular edema (DME)
Phase 2 data due late 2019.
Hereditary Angioedema (HAE)
Phase 2 trial to be initiated 1H 2020. Indication TBA.
Hereditary angioedema / Diabetic Macula Edema

Latest News

  1. KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
  2. What Type Of Shareholder Owns KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV)?
  3.  KalVista Pharmaceuticals Announces Changes to Board of Directors
  4. Hedge Funds Have Never Been This Bullish On KalVista Pharmaceuticals, Inc. (KALV)
  5. KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology
  6. KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
  7. KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop
  8. KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
  9. Rigel Initiates Enrollment in Pivotal Blood Disorder Study
  10. KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why
  11. SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...
  12. Small Drug Stocks Outlook: Near-Term Prospects Encouraging
  13. KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019
  14. KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
  15. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  16. KalVista Pharmaceuticals to Present at Needham Healthcare Conference
  17. Recent Analysis Shows Wells Fargo, Public Service Enterprise Group, Apartment Investment and Management, Gentherm, Connecticut Water Service, and KalVista Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  18. KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer
  19. What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?
  20. Is KalVista Pharmaceuticals’s (NASDAQ:KALV) 147% Share Price Increase Well Justified?